Jeffrey Lance Anderson, MD
May 23rd, 2012
Panel: Azithromycin and Cardiovascular Risk
Paul Sax, MD, Joseph S. Ross, MD, MHS and Jeffrey Lance Anderson, MD
Three experts offer perspective on a large database study showing an association between azitrhromycin use and increased risk for cardiovascular death.
August 11th, 2010
What Do Cardiologists Need to Know About 9p21?
Jeffrey Lance Anderson, MD
CardioExchange welcomes Jeffrey Anderson to discuss his recent editorial in the Journal of the American College of Cardiology on the 9p21 locus and CHD. Dr. Anderson and co-author Benjamin Horne carefully evaluated the relationship of 9p21 to CHD and conclude that 9p21 appears to be an initiator of and may be a promoter of CHD, […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?